[{"id":"d05cd91b-b021-430e-af34-c3bacc60234c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03824964","created_at":"2021-01-18T18:53:30.847Z","updated_at":"2024-07-02T16:37:03.291Z","phase":"Phase 1","brief_title":"Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma","source_id_and_acronym":"NCT03824964","lead_sponsor":"Allife Medical Science and Technology Co., Ltd.","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti CD19/CD22 CAR NK cells"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2019-01-31"}]